GlassScriptPhysician profile
Latrice Janiva Shell
NPI 1528783065
$3,988.52
in general payments reported to CMS, 2019-2025
27 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $33.78 · 2023: $2,004 · 2024: $1,740 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,954.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $825.05 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $417.39 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $265.43 | 2023-2024 | |
| Glaxosmithkline, LLC. | $260.15 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $209.32 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $190.67 | 2023-2024 | Xarelto |
| Novo Nordisk INC | $186.95 | 2023-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.85 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $169.13 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.17 | 2023-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $128.56 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.20 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $119.96 | 2022-2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $107.90 | 2023-2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $104.46 | 2024 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $100.15 | 2023-2024 | Repatha, Otezla |
| Esperion Therapeutics, INC. | $92.16 | 2023-2024 | Nexletol |
| Azurity Pharmaceuticals, INC. | $78.32 | 2023-2024 | Horizant, Horizant |
| Cequr Corporation | $66.00 | 2023-2024 | Cequr Simplicity |
| Astellas Pharma US INC | $48.49 | 2024 | Veozah |
| Corcept Therapeutics | $46.63 | 2024-2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.53 | 2022-2023 | |
| Mylan Specialty L.P. | $21.20 | 2024 | Yupelri |
| Embecta Corp. | $17.52 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Merck Sharp & Dohme LLC | $15.10 | 2023 | Belsomra, Steglatro |
| Shield Therapeutics INC | $15.10 | 2024 | |
| Nestle Healthcare Nutrition INC. | $14.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latrice Shell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.